The analysis of large-scale genomic studies of the TCGA and other prostate cancer databases provided evidence that in the large majority of patients CHD1 loss and PTEN deletion (as well as AKT1, AKT2, AKT3, and PIK3CA gene alterations) were mutually exclusive [145]. This evidence concerns the gene PTEN and prostate carcinoma.